Michaela Fleming

Though weekly activity has slowed, experts insist the national activity remains high overall.

Although much attention is on coronavirus, patients might need to be more concerned with the flu.

The FDA has approved triclabendazole (Egaten) for the treatment of fascioliasis, a neglected tropical disease in patients 6 years of age and older.

The immunoassay uses automated clinical chemistry analyzers to provide a quantitative measure of plazomicin in human plasma.

James Januzzi, MD, discusses trial results from the PIONEER-HF trial and what cardiologists and hospitalists should know about sacubitril-valsartan.

Steven Nissen, MD, discusses the updates to the cholesterol guidelines and how the risk calculator should not be considered an end-all be-all.

“These guidelines bring back the concept of adjusting therapy for cholesterol levels, and they recommend more aggressive treatment targets for people in very high risk,” said Cleveland Clinic’s Steven Nissen.

When compared with enalapril, in patients with acute decompensated heart failure, sacubitril–valsartan led to greater reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP), and reduced re-hospitalization for heart failure, and was well tolerated.

Anthony Rosenzweig, MD, Chief of Cardiology at Massachusetts General Hospital discusses how exercise can protect the heart and its potential role in cardiac regeneration.

In the VITAL study, investigators found that supplementation with omega-3s and vitamin D did not meet the primary endpoint of significantly reducing major cardiovascular events or total invasive cancer.

PTSD was associated with a 3-fold increased risk of all-cause mortality or a major heart event in 12 months following cardiac arrest.

A new study emphasizes the need for specially designed syringes that ensure accuracy and precision when administering anti-VEGF agents via intravitreal injection.

R. Theodore Smith, MD, PhD, discusses the importance of developing non-invasive technologies that can detect age-related macular degeneration earlier.

While it is critical to recognize diabetic macular edema patients with delayed treatment response to reduce the progression of vision loss, improve quality of life, this may come at a cost to the institution.

After analyzing 57,925 injections administered 2013 and 2017, investigators observed an increase in aflibercept use, with a reciprocal decline in ranibizumab across all regions, while the use of bevacizumab remained stable.

The data presented at the American Academy of Ophthalmology indicates dosing IAI with treat and extend resulted in more visual acuity gains when compared to fixed dosing.

R. Theodore Smith MD, PhD, discusses the concept of hyperspectral autofluorescence imaging and how clinicians can learn more from this method than standard autofluorescence imaging.

According to an analysis of 84,228 online reviews of 7,372 ophthalmologists, the average rating for a physician with a wait time exceeding 15 minutes was 3.903.

In a new study conducted in Taiwan, investigators found that use of metformin to treat diabetes also reduced the risk of AMD development over a 13-year period.

Peter Campochiaro, MD, professor of ophthalmology and director of the retinal cell and molecular laboratory at Johns Hopkins explains the burdens of receiving frequent anti-VEGF injection treatments.

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months was 1.3 in a phase 1 cohort study.

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

In a phase 1 trial, patients in the femto-assisted crosslinking treatment arm had a more favorable outcome in the retention of corneal thickness, when compared to the conventional therapy group.

Dilsher Dhoot, MD, discusses the avenues where future research for diabetic macular edema will focus

Keith Kaye, MD, MPH discusses the current successes and challenges in addressing multidrug-resistant infections, as well as expectations for how recommendations will change in the future.

Thomas Lodise, PharmD, PhD discusses the importance of practicing risk stratification and exploring combination therapeutic options in patients with drug-resistant infections.

Kenneth Sherman, MD, PhD, discusses prevention measures for hepatitis B, managing co-infections of HIV and HCV, and recent developments to HCV screening processes